#USA #Princeton #Healthcare Access #FarmaMondo #Natalie Douglas

FarmaMondo Group Welcomes Natalie Douglas to Its Board

FarmaMondo Group, a leading international pharmaceutical organization, announced the appointment of Natalie Douglas as an independent member of its board of directors. Renowned for her pioneering work in managed access programs for pharmaceuticals, Douglas brings a wealth of experience and an impressive track record in the biotech and pharmaceutical sectors.

A Visionary in Healthcare Access

Throughout her career, Douglas has been a pivotal figure in developing models and strategies to ensure global access to vital medications. Before her new role at FarmaMondo, she founded IDIS, a pharmaceutical company based in Princeton, New Jersey. Under her leadership, IDIS became a trailblazer in the managed access market, implementing over 200 programs globally that facilitated access to treatments for rare and severe diseases. The eventual acquisition of IDIS by Clinigen Group underscored the transformative value of the framework Douglas established.

Douglas' leadership at IDIS demonstrated that expanded access could be executed systematically and ethically. She has championed access initiatives globally, connecting pharmaceutical companies with healthcare providers in remote regions, ensuring patients receive life-saving medications.

Strengthening FarmaMondo's Mission

Yaron Spigel, CEO of FarmaMondo, remarked on Douglas's significance in the context of the company's expanding networks and partnerships with U.S. pharmaceutical and biotechnology firms. "Natalie Douglas is one of the most significant figures in global patient access, recognized for establishing the industry standard for managed access programs and for bridging pharmaceutical companies with healthcare centers worldwide. Her appointment is pivotal as we broaden our partnerships and enhance our compassionate care for patients across the globe," Spigel stated.

FarmaMondo is poised for accelerated growth, particularly within the U.S. market. With 14 regional subsidiaries and a diverse portfolio encompassing oncology, specialty medicines, and rare diseases, the company serves over 50 therapeutic areas. This innovative, unparalleled access model positions FarmaMondo at the forefront of the industry, making Douglas’s experience particularly valuable.

Douglas's Commitment and Insight

In her own words, Natalie expressed her enthusiasm for contributing to FarmaMondo's mission: "It is a privilege to bring my expertise in global access to FarmaMondo and to help them expand their footprint in the U.S. market. I am impressed by what Yaron and his team have accomplished to drive the next model of international market access; FarmaMondo's work aligns with my passion for aiding patients in dire need of life-changing medications who exist outside the traditional geographies of major markets."

FarmaMondo Group is dedicated to delivering life-saving therapies to patients in more than 50 emerging markets, providing comprehensive market access solutions. Their mission reflects a commitment to serve patients who are often overlooked in global healthcare initiatives.

Conclusion

The inclusion of Natalie Douglas in FarmaMondo's board signifies a strategic move towards enhancing the organization's capabilities in patient access and global health initiatives. Her rich background aligns seamlessly with the company's goals, ensuring that FarmaMondo remains a key player in the international pharmaceutical landscape as it continues to broaden its reach and impact.

For further media inquiries, please contact:
Ivy Cohen
Ivy Cohen Corporate Communications
+1 (212) 399-0026
Email: [email protected]